Health Canada approves Jardiance tablets for adults with type 2 diabetes
Jardiance lowers the renal threshold for glucose, which leads to reduced renal reabsorption of filtered glucose and increased urinary glucose excretion.
Boehringer Ingelheim (Canada) Ltd and Eli Lilly Canada have announced that Health Canada has approved Jardiance (empagliflozin) to be used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Jardiance belongs to a new class of agents called sodium glucose co-transporter 2 (SGLT2) inhibitors that have a different mechanism of action from other oral glucose-lowering agents. Jardiance lowers the renal threshold for glucose, which leads to reduced renal reabsorption of filtered glucose and increased urinary glucose excretion.
"Although there are many medications available for the treatment of type 2 diabetes, one in two people are not achieving the recommended glycemic goals," says Dr Ronald M. Goldenberg, Endocrinologist at LMC Diabetes and Endocrinology in Thornhill, Ontario. "The approval and availability of Jardiance gives Canadian physicians another option to help improve glycemic control."
Empagliflozin was studied as a single agent (monotherapy) and in combination with other antidiabetic medications, including metformin, metformin and sulfonylurea, pioglitazone (with or without metformin), and basal and prandial insulin (with or without metformin).
Empagliflozin was also studied in patients with type 2 diabetes and cardiovascular disease, and in patients with different degrees of renal impairment.
Treatment with empagliflozin resulted in statistically significant improvements from baseline at Week 24 in HbA1c, fasting plasma glucose (FPG), and body weight across a range of background therapies. In the double-blind placebo-controlled extension of these studies, reductions of HbA1c and body weight were sustained up to Week 76. HbA1c reductions were also seen across subgroups including gender, age, race, duration of disease, and baseline BMI.
In clinical studies, the most common adverse event with empagliflozin was hypoglycaemia, which depended on the type of background therapy used in the respective studies. Other common adverse events included urinary tract infections, genital mycotic infections, increased urination, upper respiratory tract infections and dyslipidemia.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance